NextCell Pharma AB (FRA:65G)

Market Cap	10.05M -6.3%
Revenue (ttm)	842.37K -2.2%
Net Income	-3.79M
EPS	n/a
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	0.0763
Previous Close	0.0765
Day's Range	0.0763 - 0.0763
52-Week Range	0.0462 - 0.1674
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 27, 2026

About NextCell Pharma AB

NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of stromal cell therapies in Sweden. Its lead drug candidate is ProTrans, a cell therapy with mesenchymal stromal cells for the treatment of autoimmune and inflammatory diseases, including type-1 diabetes. The company also operates Cellaviva, a stem cell bank; and QVance, the first dedicated provider of quality services for developers of advanced therapies. The company was incorporated in 2014 and is headquartered in Huddinge, Sweden.

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2014
• Employees: 24
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 65G

Financial Performance

In 2025, NextCell Pharma AB's revenue was 9.83 million, a decrease of -11.13% compared to the previous year's 11.06 million. Losses were -38.79 million, 10.4% more than in 2025.

Financial numbers in SEK

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Jun 27, 2026

Data Sources Report a data error